GSK3326595

DRUG3 trials

Sponsors

GlaxoSmithKline, Ottawa Hospital Research Institute

Conditions

Breast CancerNeoplasms

Phase 1

An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma

CompletedNCT02783300

GlaxoSmithKlineNeoplasms

Start: 2016-08-30End: 2023-08-30Updated: 2025-03-10

Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

TerminatedNCT03614728

GlaxoSmithKlineNeoplasms

Start: 2018-10-16End: 2022-01-11Updated: 2023-02-06

Phase 2

A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer

CompletedNCT04676516

Ottawa Hospital Research InstituteBreast Cancer

Start: 2021-06-08End: 2022-08-15Updated: 2022-10-25

Related Papers

Phase Ib and dose-expansion study of GSK3326595, a PRMT5 inhibitor as monotherapy and in combination with pembrolizumab in patients with advanced cancers.

2025-09-093 citations

Phase I/II study of the clinical activity and safety of GSK3326595 in patients with myeloid neoplasms.

2024-09-1417 citations

Abstract P6-05-12: Understanding Patient Perspectives on Window of Opportunity Clinical Trial Participation in Breast Cancer

Cancer Research2023-03-01

A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Syndrome and Acute Myeloid Leukemia

Blood2019-11-1341 citations

Abstract CT038: A phase I, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of GSK3326595 in subjects with solid tumors and non-Hodgkin's lymphoma

Cancer Research2017-07-0116 citations